Last updated on May 2017

Study to Investigate Safety Tolerability Pharmacodynamics and Pharmacokinetics of GSK2646264


Brief description of study

This First Time in Human (FTIH) study, which will be performed in three parts, is designed to investigate the safety, local tolerability, pharmacokinetics and pharmacodynamics after single and repeat topical applications of up to 2 strengths of GSK2646264 and corresponding placebo within the same subject, in healthy adult subjects (Part A), subjects with cold urticaria (CU, Part B) and subjects with chronic spontaneous urticaria (CsU, Part C). The study will also measure short term effects of GSK2646264 on the number and size of weals in subjects with CsU, and in healthy subjects and subjects with CU following provocation tests.

Clinical Study Identifier: NCT02424799

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

US GSK Clinical Trials Call ...

GSK Investigational Site
Berlin, Germany
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Norwich, United Kingdom
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
London, United Kingdom
  Connect »